1. DOP007 Efficacy of vedolizumab induction therapy on clinical and endoscopic activity in patients with anti-tumour necrosis factor alpha-resistant inflammatory bowel disease. (16th January 2018) Authors: Bor, R; Klaudia, F; Miheller, P; Palatka, K; Szamosi, T; Vincze, Á; Rutka, M; Szántó, K; Bálint, A; Szepes, Z; Nagy, F; Milassin, Á; Fábián, A; Csontos, Á; Golovics, P; Lakner, L; Müllner, K; Papp, M; Salamon, Á; Sarang, K Journal: Journal of Crohn's and colitis Issue: Volume 12:Number 1(2018:Jan.)Supplement 1 Page Start: S034 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P441 Clinical efficacy, drug sustainability and results from therapeutic drug monitoring in Crohn's disease patients treated with ustekinumab – 1-year follow-up of a prospective, nationwide, multicenter cohort from Hungary. (27th May 2021) Authors: Gonczi, L; Szanto, K; Farkas, K; Molnar, T; Szamosi, T; Schafer, E; Golovics, P; Lovasz, B; Patai, A; Vincze, A; Sarlos, P; Farkas, A; Dubrovcsik, Z; Tóth G, T; Lakatos, P L; Miheller, P; Ilias, A Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S441 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P534 IBD-related malignancies observed in 2015–2018: 4 years' results from the prospective nationwide Hungarian registry. (25th January 2019) Authors: Milassin, A; Rutka, M; Farkas, K; Bálint, A; Bor, R; Fábián, A; Szepes, Z; Szamosi, T; Szántó, K; Miheller, P; Barta, Z; Banai, J; Kovács, Á; Salamon, Á; Lakatos, L; Lakner, L; Palatka, K; Papp, M; Schafer, E; Novák, J Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S380 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P578 Non-medical switch between adalimumab biosimilars and from the originator adalimumab to biosimilars in inflammatory bowel disease patients – a multicentre study on efficacy and drug sustainability. (21st January 2022) Authors: Lontai, L; Gonczi, L; Balogh, F; Komlodi, N; Resal, T; Farkas, K; Molnar, T; Golovics, P; Schafer, E; Szamosi, T; Miheller, P; Ilias, A; Lakatos, P L Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i518 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P694 Non-medical mandatory reversed and back and forth switch between infliximab and its biosimilar: Early clinical outcomes. (16th January 2018) Authors: Ilias, A; Szanto, K; Gonczi, L; Kurti, Z; Golovics, P A; Schafer, E; Farkas, K; Szamosi, T; Szepes, Z; Molnar, T; Vincze, A; Lakatos, P L Journal: Journal of Crohn's and colitis Issue: Volume 12:Number 1(2018:Jan.)Supplement 1 Page Start: S461 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗